{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T19:35:34Z","timestamp":1774899334599,"version":"3.50.1"},"reference-count":20,"publisher":"Japanese Circulation Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2022,8,25]]},"DOI":"10.1253\/circj.cj-21-1004","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T22:09:46Z","timestamp":1652738986000},"page":"1352-1361","source":"Crossref","is-referenced-by-count":7,"title":["Early P2Y&lt;sub&gt;12&lt;\/sub&gt; Inhibitor Single Antiplatelet Therapy for High-Bleeding Risk Patients After Stenting\u3000\u2015 PENDULUM Mono 24-Month Analysis \u2015"],"prefix":"10.1253","volume":"86","author":[{"given":"Yoshihisa","family":"Nakagawa","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Shiga University of Medical Science"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazushige","family":"Kadota","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kurashiki Central Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Nakao","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Shite","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Osaka Saiseikai Nakatsu Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyoshi","family":"Yokoi","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine Center, Fukuoka Sanno Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Kozuma","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Teikyo University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Tanabe","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Mitsui Memorial Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Akasaka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Wakayama Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiro","family":"Shinke","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Showa University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Ueno","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukuoka Kinen Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Hirayama","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Osaka Police Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Uemura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kawasaki Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raisuke","family":"Iijima","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Toho University Ohashi Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Harada","sequence":"additional","affiliation":[{"name":"Medical Information Department, Daiichi Sankyo Co., Ltd"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kuroda","sequence":"additional","affiliation":[{"name":"Primary Medical Science Department, Daiichi Sankyo Co., Ltd"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Takita","sequence":"additional","affiliation":[{"name":"Data Intelligence Department, Daiichi Sankyo Co., Ltd"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, School of Medicine, Toho University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Saito","sequence":"additional","affiliation":[{"name":"Division of Cardiology and Catheterization Laboratories, Shonan Kamakura General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Toho University Ohashi Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting: Stent Anticoagulation Restenosis Study Investigators. <i>N Engl J Med<\/i> 1998; 339: 1665\u20131671.","DOI":"10.1056\/NEJM199812033392303"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. <i>N Engl J Med<\/i> 2014; 371: 2155\u20132166.","DOI":"10.1056\/NEJMoa1409312"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Palmerini T, Benedetto U, Bacchi-Reggiani L, Della Riva D, Biondi-Zoccai G, Feres F, et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: A pairwise and Bayesian network meta-analysis of randomized trials. <i>Lancet<\/i> 2015; 385: 2371\u20132382.","DOI":"10.1016\/S0140-6736(15)60263-X"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Toyota T, Shiomi H, Morimoto T, Natsuaki M, Kimura T. Short versus prolonged dual antiplatelet therapy (DAPT) duration after coronary stent implantation: A comparison between the DAPT study and 9 other trials evaluating DAPT duration. <i>PLoS One<\/i> 2017; 12: e0174502.","DOI":"10.1371\/journal.pone.0174502"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Nakamura M, Kimura K, Kimura T, Ishihara M, Otsuka F, Kozuma K, et al. JCS 2020 guideline focused update on antithrombotic therapy in patients with coronary artery disease. <i>Circ J<\/i> 2020; 84: 831\u2013865.","DOI":"10.1253\/circj.CJ-19-1109"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: The STOPDAPT-2 randomized clinical trial. <i>JAMA<\/i> 2019; 321: 2414\u20132427.","DOI":"10.1001\/jama.2019.8145"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. <i>N Engl J Med<\/i> 2019; 381: 2032\u20132042.","DOI":"10.1056\/NEJMoa1908419"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kang J, Park KW, Palmerini T, Stone GW, Lee MS, Colombo A, et al. Racial differences in ischaemia\/bleeding risk trade-off during anti-platelet therapy: Individual patient level landmark meta-analysis from seven RCTs. <i>Thromb Haemost<\/i> 2019; 119: 149\u2013162.","DOI":"10.1055\/s-0038-1676545"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kohsaka S, Miyata H, Ueda I, Masoudi FA, Peterson ED, Maekawa Y, et al. An international comparison of patients undergoing percutaneous coronary intervention: A collaborative study of the National Cardiovascular Data Registry (NCDR) and Japan Cardiovascular Database-Keio interhospital Cardiovascular Studies (JCD-KiCS). <i>Am Heart J<\/i> 2015; 170: 1077\u20131085.","DOI":"10.1016\/j.ahj.2015.09.017"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Mak KH, Bhatt DL, Shao M, Hankey GJ, Easton JD, Fox KAA, et al. Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study. <i>Am Heart J<\/i> 2009; 157: 658\u2013665.","DOI":"10.1016\/j.ahj.2008.08.031"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Antithrombotic Trialists\u2019 (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomized trials. <i>Lancet<\/i> 2009; 373: 1849\u20131860.","DOI":"10.1016\/S0140-6736(09)60503-1"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Nakamura M, Kadota K, Nakao K, Nakagawa Y, Shite J, Yokoi H, et al. Single antiplatelet therapy with prasugrel vs. dual antiplatelet therapy in Japanese percutaneous coronary intervention patients with high bleeding risk. <i>Circ J<\/i> 2021; 85: 785\u2013793.","DOI":"10.1253\/circj.CJ-20-1058"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Nakamura M, Morino Y, Kakuta T, Hata Y, Takamisawa I, Tanabe K, et al. Monotherapy with prasugrel after dual-antiplatelet therapy for Japanese percutaneous coronary intervention patients with high bleeding risk: A prospective cohort study (PENDULUM mono study). <i>Circ J<\/i> 2021; 85: 27\u201336.","DOI":"10.1253\/circj.CJ-20-0786"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Nakamura M, Kadota K, Takahashi A, Nakamura M, Kadota K, Takahashi A, et al. Relationship between platelet reactivity and ischemic and bleeding events after percutaneous coronary intervention in East Asian patients: 1-year results of the PENDULUM registry. <i>J Am Heart Assoc<\/i> 2020; 9: e015439.","DOI":"10.1161\/JAHA.119.015439"},{"key":"15","unstructured":"15. ICH Expert Working Group. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6(R1). https:\/\/www.pmda.go.jp\/files\/000156725.pdf (accessed April 11, 2022)."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Nakamura M, Kadota K, Nakao K, Nakagawa Y, Shite J, Yokoi H, et al. High bleeding risk and clinical outcomes in East Asian patients undergoing percutaneous coronary intervention: The PENDULUM registry. <i>EuroIntervention<\/i> 2021; 16: 1154\u20131162.","DOI":"10.4244\/EIJ-D-20-00345"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Mehran R, Baber U, Steg PG, Ariti C, Weisz G, Witzenbichler B, et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. <i>Lancet<\/i> 2013; 382: 1714\u20131722.","DOI":"10.1016\/S0140-6736(13)61720-1"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kaikita K, Yasuda S, Akao M, Ako J, Matoba T, Nakamura M, et al. Bleeding and subsequent cardiovascular events and death in atrial fibrillation with stable coronary artery disease: Insights from the AFIRE trial. <i>Circ Cardiovasc Interv<\/i> 2021; 14: e010476.","DOI":"10.1161\/CIRCINTERVENTIONS.120.010476"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Koo BK, Kang J, Park KW, Rhee TM, Yang HM, Won KB et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): An investigator-initiated, prospective, randomised, open-label, multicentre trial. <i>Lancet<\/i> 2021; 397: 2487\u20132496.","DOI":"10.1016\/S0140-6736(21)01063-1"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Tomaniak M, Chichareon P, Onuma Y, Deliargyris EN, Takahashi K, Kogame N, et al. Benefit and risks of aspirin in addition to ticagrelor in acute coronary syndromes: A post hoc analysis of the randomized GLOBAL LEADERS trial. <i>JAMA Cardiol<\/i> 2019; 4: 1092\u20131101.","DOI":"10.1001\/jamacardio.2019.3355"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/86\/9\/86_CJ-21-1004\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T04:44:15Z","timestamp":1661575455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/86\/9\/86_CJ-21-1004\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-21-1004","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,25]]},"article-number":"CJ-21-1004"}}